Niacin and Selenium Combination Therapy in Patients With Septic Shock (NISE-1)
Combination Therapy of Niacin and Selenium in Patients With Septic Shock (Phase IIa Single Center Double-blind Randomized Controlled Trial)
This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.
The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.
Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.
The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.
Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.
The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: WOON YONG KWON, MD, PhD
- Numer telefonu: 82-2-2072-0326
- E-mail: kwy711@hanmail.net
Kopia zapasowa kontaktu do badania
- Nazwa: Hayoung Kim, MD, PhD
- Numer telefonu: 82-2-2072-3257
- E-mail: mogu13@naver.com
Lokalizacje studiów
-
-
-
Seoul, Korea Południowa, 03080
- Seoul National University Hospital
-
Kontakt:
- WOON YONG KWON, MD, PhD
- Numer telefonu: 82-2-2072-0326
- E-mail: kwy711@hanmail.net
-
Kontakt:
- Hayoung Kim, MD, PhD
- Numer telefonu: 82-2-2072-3257
- E-mail: mogu13@naver.com
-
Główny śledczy:
- WOON YONG KWON, MD, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 19 years or older, irrespective of sex or race.
- Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:
Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.
Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.
A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.
Written informed consent provided by the participant or an authorized representative.
Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Age younger than 19 years.
- Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit.
- Expected death within 72 hours because of the severity of illness.
- Patients for whom aggressive treatment is not being provided in accordance with an advance directive.
- Known pre-existing liver failure with a Child-Pugh score of 10 or greater.
- Lack of informed consent from the participant or an authorized representative.
- Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Niacin plus Selenium
Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock. |
Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. |
|
Komparator placebo: Placebo
Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock. |
Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7
Ramy czasowe: Hospital day 7
|
Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission. |
Hospital day 7
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
28-Day Survival
Ramy czasowe: From hospital admission (hospital day 0) through day 28
|
Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method. |
From hospital admission (hospital day 0) through day 28
|
|
90-Day Survival
Ramy czasowe: From hospital admission (hospital day 0) through day 90
|
Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method. |
From hospital admission (hospital day 0) through day 90
|
|
Length of Intensive Care Unit Stay
Ramy czasowe: From hospital admission (hospital day 0) through hospital day 90
|
Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90. |
From hospital admission (hospital day 0) through hospital day 90
|
|
Duration of Mechanical Ventilation
Ramy czasowe: From hospital admission (hospital day 0) through hospital day 90
|
Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90. |
From hospital admission (hospital day 0) through hospital day 90
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pharmacologic, Antioxidant, and Mechanistic Biomarkers
Ramy czasowe: At enrollment, 72 hours (±6 hours), and day 7
|
Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels. |
At enrollment, 72 hours (±6 hours), and day 7
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: WOON YONG KWON, MD, PhD, Seoul National University Hospital
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Infekcje
- Posocznica
- Zespół ogólnoustrojowej reakcji zapalnej
- Zapalenie
- Zaszokować
- Stany patologiczne, oznaki i objawy
- Szok, septyczny
- Pirydyny
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Chemikalia nieorganiczne
- Elementy
- Chalcogeny
- Minerały
- Kwasy, heterocykliczne
- Kwasy nikotynowe
- Niacyna
- Selen
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- SNUH-NISE-2026
- 2509-096-1679 (Inny identyfikator: Seoul National University Hospital Institutional Review Board)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.
Ramy czasowe udostępniania IPD
De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.
Kryteria dostępu do udostępniania IPD
De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .